Literature DB >> 31268408

Prevalence and Genetic Relatedness of Extended Spectrum-β-Lactamase-Producing Escherichia coli Among Humans, Cattle, and Poultry in Pakistan.

Muhammad Umair1, Mashkoor Mohsin1, Qasim Ali1, Muhammad Usman Qamar2, Shahbaz Raza1, Aamir Ali3, Sebastian Guenther4,5, Peter Schierack6.   

Abstract

Objective: To determine the prevalence and genetic relatedness of blaCTX-M-type extended spectrum-β-lactamase (ESBL)-producing Escherichia coli at the human-animal interface in Pakistan. Materials and
Methods: A total of 150 human, cattle, and poultry fecal samples (50 each) were screened for ESBL-producing E. coli using ESBL CHROMagar®. Bacterial species confirmation as well as determination of minimum inhibitory concentrations (μg/mL) to different antibiotics was performed using the automated VITEK®-2 compact system. Phenotypic confirmation of ESBL production was performed according to the Clinical Laboratory Standards Institute (CLSI) guidelines. Genetic analysis of blaCTX-M was carried out by PCR and DNA sequencing. Plasmids and clonal similarity of the E. coli strains were determined by PCR-based replicon typing and pulsed-field gel electrophoresis (PFGE), respectively.
Results: Of 150 samples, 29 (19.3%) ESBL-producing E. coli were recovered, and majority of them originated from human (n = 16; 55%), followed by cattle (n = 9; 31%) and poultry (n = 4; 13.7%). blaCTX-M-15 was predominant ESBL genotype (n = 25; 86.2%), mainly identified from human (n = 15) and cattle (n = 9). This is also the first report of the occurrence of CTX-M-15 and CTX-M-55 in cattle and poultry E. coli isolates of Pakistan, respectively. The majority of the ESBL-producing E. coli (96.5%) showed a multidrug resistance phenotype. All isolates carried IncFII or IncFIA plasmids, and the phylogroup B1 was dominant (44.8%) followed by phylogroups A (31%), D (17.2%), and B2 (6.8%). PFGE revealed that isolates from different hosts were genetically unrelated.
Conclusion: Presence of CTX-M-15-type ESBL-producing E. coli in different reservoirs is alarming and has the potential to impact both veterinary and human therapeutic treatment options.

Entities:  

Keywords:  Escherichia coli; MIC; blaCTX-M; genetic relatedness; replicon typing

Mesh:

Substances:

Year:  2019        PMID: 31268408     DOI: 10.1089/mdr.2018.0450

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

1.  Genetic relatedness of multidrug resistant Escherichia coli isolated from humans, chickens and poultry environments.

Authors:  Mabel Kamweli Aworh; Jacob K P Kwaga; Rene S Hendriksen; Emmanuel C Okolocha; Siddhartha Thakur
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-23       Impact factor: 4.887

2.  The Escherichia coli Sequence Type 131 Harboring Extended-Spectrum Beta-Lactamases and Carbapenemases Genes from Poultry Birds.

Authors:  Sana Ilyas; Muhammad Hidayat Rasool; Muhammad Javed Arshed; Muhammad Usman Qamar; Bilal Aslam; Ahmad Almatroudi; Mohsin Khurshid
Journal:  Infect Drug Resist       Date:  2021-03-02       Impact factor: 4.003

3.  Molecular analysis of blaSHV, blaTEM, and blaCTX-M in extended-spectrum β-lactamase producing Enterobacteriaceae recovered from fecal specimens of animals.

Authors:  Hasan Ejaz; Sonia Younas; Khalid O A Abosalif; Kashaf Junaid; Badr Alzahrani; Abdullah Alsrhani; Abualgasim Elgaili Abdalla; Muhammad Ikram Ullah; Muhammad Usman Qamar; Sanaa S M Hamam
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

4.  Multidrug-resistant enterobacteria in newborn dairy calves in Germany.

Authors:  Jil Waade; Uwe Seibt; Walther Honscha; Fanny Rachidi; Alexander Starke; Stephanie Speck; Uwe Truyen
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

5.  Genomic characterization of high-risk Escherichia coli and Enterobacter hormaechei clones recovered from a single tertiary-care hospital in Pakistan.

Authors:  Mashkoor Mohsin; Brekhna Hassan; Ali Usman Khan; Arslan Ali; Göte Swedberg; Badrul Hasan
Journal:  J Appl Microbiol       Date:  2022-02-21       Impact factor: 4.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.